Statement of Principles concerning pure red cell aplasia (Reasonable Hypothesis) (No. 60 of 2020)

Reasonable hypothesis. This is the standard of proof applicable to claims under section 120A of the VEA for veterans with operational service. The SoP determines what factors can support a reasonable hypothesis. The RMA must be satisfied that there is sound medical‑scientific evidence indicating that the condition can be related to relevant service (section 8). The instrument itself does not define "reasonable hypothesis" but institutes the minimum factors that must exist.

Clinical onset versus clinical worsening. The factors are divided between onset (factors 1 to 11) and worsening (factors 12 and 13). Onset factors relate to the first appearance of PRCA. Worsening factors apply only where the person's PRCA was suffered or contracted before or during (but did not arise out of) relevant service, as stated in section 10(2). This distinction matters for veterans who had PRCA before service and whose condition deteriorated during service.

Relevant service. The instrument defines relevant service by reference to the VEA and MRCA: operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA. This list is exhaustive. Service outside these categories does not allow the SoP to be used, although claims under other provisions may still be possible.

Pure red cell aplasia. The definition in subsection 7(2) is the exclusive meaning for the purposes of the instrument, overriding any other clinical or coding definition. The exclusion of certain conditions (Diamond‑Blackfan anaemia, myelodysplastic syndrome, paroxysmal nocturnal haemoglobinuria) prevents claimants from repackaging those conditions as PRCA. The instrument also treats death from PRCA as inclusive of terminal events contributed to by the condition, with a prescribed list in the dictionary.

Factors that must exist. Section 9 lists 13 factors. These include pregnancy, treatment with specified drugs, non‑aspirin NSAID use, benzene exposure, acute hepatitis, liver transplant, autoimmune disease (from a specified list), haematological malignancy (from a specified list), thymoma or thymic carcinoma, parvovirus B19 infection or acute infectious mononucleosis, and inability to obtain appropriate clinical management. Each factor has specific timeframes, frequency, or dosage conditions. For instance, benzene exposure requires cutaneous contact with liquids containing more than 1% benzene by volume, or inhalation at an 8‑hour time‑weighted average concentration exceeding 5 parts per million, on at least 30 days in the year before onset.

Specified drugs. Schedule 2 includes 37 entries, many broad categories (alkylating agents, antimetabolite agents, immune checkpoint inhibitors) and individual drugs (azathioprine, carbamazepine, chloramphenicol, etc.). For factors 2 and 3, the drug must be administered within the specified timeframe. Factor 3 is a generic pathway: any drug not on the list can qualify if it is associated in the individual with development of PRCA within six months of therapy and improvement within six months of discontinuing or tapering. This provides a safety net for idiosyncratic drug reactions.

The primary persons affected are current and former members of the Australian Defence Force, peacekeepers, and British nuclear test defence participants who have rendered relevant service as defined in the dictionary. Specifically, persons who served in operational service, peacekeeping service, hazardous service, or British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA, and who develop PRCA or die from it. Veterans with peacetime service only (not falling within those categories) cannot rely on this SoP, although they might have other pathways under different standards of proof.

The instrument also directly affects decision‑makers: the Repatriation Commission, the Veterans' Review Board, and the Administrative Appeals Tribunal. When assessing a claim for PRCA, these bodies must apply this SoP. It constrains their discretion: they cannot find a reasonable hypothesis unless at least one factor in section 9 exists and is related to service. For MRCA claims, section 338 of that Act similarly mandates application. This reduces the evidentiary burden on claimants compared to a standard common‑law tort approach, because the factors are predetermined rather than requiring proof of causation de novo. However, it also means that claimants whose circumstances do not match any listed factor are excluded, regardless of potential medical plausibility.

Medical practitioners who provide evidence in support of claims are indirectly affected. Their reports must address the specific definitions and timeframes in the SoP. For example, stating that a veteran has PRCA coded as D60 is not enough; the report must confirm the absence of excluded conditions and, if relying on a drug factor, identify the drug and the timing. The RMA's view that there is sound medical‑scientific evidence for these factors is embedded in the instrument (section 8), so practitioners do not need to re‑prove the general causal relationship; they only need to link the individual's circumstances to the factor.

Legal practitioners, advocates, and veterans' representatives must be familiar with the precise wording. A factor like "being exposed to benzene as specified" involves a detailed definition with a concentration threshold of 5 parts per million for an 8‑hour TWA. A slight misunderstanding could lead to an unsuccessful claim. The instrument also affects the Department of Veterans' Affairs, which must process claims efficiently against these criteria. Finally, the pharmaceutical industry may be tangentially affected because the list of specified drugs in Schedule 2 includes many common medications; this could influence prescribing patterns in military settings, though the effect is likely small given the rarity of PRCA.

The instrument does not impose duties directly on individuals. The relevant duties lie on the Repatriation Commission and other decision‑makers: they must not accept a reasonable hypothesis for PRCA unless at least one factor in section 9 exists and is related to service. This duty is enforceable through merits review and judicial review. Claimants have a right to have their claim determined in accordance with this SoP. If a decision‑maker fails to apply the correct SoP version (e.g. using the repealed 2012 SoP for aplastic anaemia), the claimant can argue legal error.

Claimants also have a right to rely on any of the 13 factors. They are not required to prove the factor to the civil standard (balance of probabilities) at the reasonable hypothesis stage; rather, they must raise a reasonable hypothesis connecting the factor to service. However, the factor itself must be established on the balance of probabilities for the claim to succeed in final determination. The instrument does not address the standard of proof for the factor itself; that is governed by general principles under the VEA and MRCA.

Section 10(2) imposes a limitation: factors 12 and 13 (pregnancy at clinical worsening, inability to obtain appropriate clinical management) apply only to material contribution to or aggravation of pre‑existing PRCA. This means a veteran who already had PRCA before service cannot use those factors to claim onset, only to claim worsening. This distinction is a trap for those unfamiliar with the instrument.

Section 11 grants a right to incorporate other SoPs. If a factor in section 9 refers to an injury or disease that has its own SoP (for example, an autoimmune disease or haematological malignancy), then the factors in that other SoP also apply. This cross‑referencing means that a claimant for PRCA may need to satisfy two or more SoPs, which can complicate the claim. However, it also allows the claimant to use factors from another SoP if the underlying condition was itself service‑related.

This instrument contains no penalty provisions. Enforcement is indirect: failure to comply with its terms by a decision‑maker results in the claim being determined without lawful authority, opening it to appeal. There are no penalties for claimants who misrepresent facts, but the VEA and MRCA contain separate provisions for false statements and penalties for veterans or medical practitioners who provide false evidence (e.g. sections 210‑214 of the VEA). Those penalties are not part of this SoP.

From an enforcement perspective, the primary mechanism is review. Veterans dissatisfied with a decision that applies (or fails to apply) this SoP can seek review by the Veterans' Review Board and then the Administrative Appeals Tribunal, and ultimately the Federal Court on a question of law. The instrument's rigid factor list reduces the scope for discretionary errors but increases the likelihood of jurisdictional error if a decision‑maker misinterprets a definition.

This SoP is made under subsection 196B(2) of the VEA. It interacts directly with section 120A of the VEA and section 338 of the MRCA, which require the SoP to be applied. It also interacts with other SoPs as noted in section 11: where a factor refers to a condition that is the subject of its own SoP, that SoP must be applied. This creates a cascading effect. For example, factor 8 requires having an autoimmune disease from the specified list. That autoimmune disease (e.g. systemic lupus erythematosus) may have its own SoP. A claimant who relies on that factor must satisfy the lupus SoP as well, unless the lupus is not the subject of a SoP (the instrument does not list which autoimmune diseases have SoPs; it says "if a factor refers to an injury or disease in respect of which a Statement of Principles has been determined"). This interacts with the broader regulatory framework administered by the RMA, which issues SoPs for hundreds of conditions.

The instrument also interacts with the Social Security Act 1991 and related legislation indirectly: veterans who receive compensation under VEA or MRCA may have their social security payments affected under the compensation recovery provisions. The SoP itself does not govern that interaction, but a successful claim for PRCA will trigger those provisions.

The instrument explicitly excludes the conditions listed in subsection 7(2)(b) - congenital Diamond‑Blackfan anaemia, myelodysplastic syndrome, and paroxysmal nocturnal haemoglobinuria - meaning those conditions must be considered under their own SoPs if they exist.

The repeal clause (section 4) revokes the previous SoP for aplastic anaemia No. 50 of 2012. However, claims in progress before 28 September 2020 may still be determined under the repealed instrument if transitional provisions apply (the instrument does not specify, but the VEA generally provides that the SoP in force at the time of claim applies). The interaction with state workers' compensation schemes is not addressed; the SoP only applies to federal military service matters.

The source provides only the current instrument and notes in section 4 the repeal of the "Statement of Principles concerning aplastic anaemia No. 50 of 2012". That earlier instrument covered aplastic anaemia, not pure red cell aplasia, which is a distinct condition. The current SoP is No. 60 of 2020 and was determined on 28 August 2020, with commencement on 28 September 2020. There is no indication of amendments to this instrument itself. The RMA typically issues new SoPs or amendments periodically, but none are referenced. The instrument also cites the ICD‑10‑AM Tenth Edition effective 1 July 2017, which suggests that any future updates to the coding classification would not automatically amend the SoP; a new SoP would need to be issued. Practitioners must check whether the RMA has issued a subsequent SoP for PRCA after 2020, as this deep dive is based solely on the provided text.

The source contains no references to any case law or litigation history. Statements of Principles are frequently challenged in the Veterans' Appeals Division of the Administrative Appeals Tribunal and the Federal Court on grounds including whether the RMA had power to make the SoP, whether the factors are supported by sound medical‑scientific evidence, and whether the wording is ambiguous. However, no such challenges are documented in the instrument. The absence of litigation history in the source means we cannot identify any authoritative interpretations of this particular SoP. Practitioners should note that previous SoPs have been litigated over issues such as the meaning of "clinical onset" and "material contribution", and similar arguments may arise under this SoP. The narrow definition of PRCA may be a focal point for future disputes, particularly over what constitutes "nearly complete" cessation of red cell production or what counts as "rare" erythroid precursor cells. The exclusion of myelodysplastic syndrome from PRCA may be contentious where a claimant has both conditions. However, without case citations from the source, this section remains a contextual note rather than a claim of actual litigation.

Several details could trap claimants and practitioners.

First, the definition of PRCA in subsection 7(2) excludes three conditions. A veteran diagnosed with Diamond‑Blackfan anaemia, myelodysplastic syndrome, or paroxysmal nocturnal haemoglobinuria cannot succeed under this SoP, even if the symptoms overlap. It also excludes any condition not meeting the precise description: "complete or nearly complete cessation of red cell production ... without effects on other haematopoietic cells". A claim based on mild or moderate red cell aplasia would fail.

Second, the timeframes for factors are strict and non‑flexible. Factor 2 requires treatment with a specified drug "within the one year before the clinical onset". A gap of 366 days would not satisfy it. Factor 4 requires NSAID use for at least four days per week for at least four weeks, within one year before onset. Occasional or intermittent use below the threshold is insufficient.

Third, benzene exposure is defined with a concentration threshold: mandatory exposure to an 8‑hour TWA exceeding 5 parts per million, or cutaneous/ingestion contact with liquid containing more than 1% by volume. Many military exposures may involve lower concentrations or intermittent peaks that do not average above the threshold. The 30 day minimum in the year before onset must also be met.

Fourth, factor 3 (drug not on Schedule 2) imposes two conditions simultaneously: development of PRCA within six months of starting the drug and improvement within six months of stopping or tapering. Both elements must be proven. If a veteran improves without tapering or if the drug is not discontinued, the factor fails.

Fifth, factor 13 (inability to obtain appropriate clinical management) applies only to clinical worsening, not to onset. Furthermore, section 10(2) limits factors 12 and 13 to cases where the person's PRCA was suffered or contracted before or during (but did not arise out of) relevant service. That means a veteran who first contracted PRCA during service cannot use factor 12 or 13 at all; only onset factors (1‑11) are available.

Sixth, the instrument is an SoP for the reasonable hypothesis standard, not for the balance of probabilities standard used for peacetime service or MRCA non‑warlike service claims. Those claims may have a different standard, but the SoP still applies. The instrument does not explain that distinction, which could cause confusion.

Seventh, the interaction with other SoPs (section 11) means that a claimant relying on factor 8 (autoimmune disease) must also satisfy the SoP for that autoimmune disease, if one exists. Many autoimmune diseases have their own SoPs with different factor lists. This multiplies the evidentiary burden.

Eighth, the dictionary defines "being exposed to benzene as specified" with a note cross‑referencing "8‑hour time‑weighted average (TWA)", which is itself defined as "the averaging of different exposure levels to benzene during an average exposure period equivalent to eight hours". The definition is ambiguous about whether the TWA must be measured in a specific area or for the person individually, and whether occasional peaks above the threshold but averaging below it count. This ambiguity leaves room for adverse findings.

Ninth, the list of specified drugs includes broad categories like "alkylating agents" and "antimetabolite agents" without full enumeration, only examples in parentheses. A drug that falls within the class but is not listed by name could still be captured if a medical practitioner identifies it as such. However, the burden falls on the claimant to prove the drug belongs to that class.

Compliance with this instrument is relevant primarily to two groups: decision‑makers (the Repatriation Commission) and legal representatives guiding claimants. For decision‑makers, compliance means ensuring that each claim for PRCA is assessed against the current SoP (No. 60 of 2020) and that at least one factor in section 9 is identified and found to exist on the evidence. The decision‑maker must also ensure that the factor is related to the person's relevant service, as required by section 10. This involves checking the definitions in the dictionary: e.g. confirming that "being exposed to benzene as specified" meets the quantitative and temporal requirements. For factors relying on other SoPs (section 11), the decision‑maker must apply those SoPs as in force from time to time.

For claimants and their representatives, compliance means marshalling evidence that matches one of the factors precisely. The following steps are advisable:

1. Obtain a formal diagnosis of pure red cell aplasia that meets the subsection 7(2) definition, including haematological evidence of absent or rare erythroid precursors and exclusion of Diamond‑Blackfan anaemia, myelodysplastic syndrome, and paroxysmal nocturnal haemoglobinuria. The ICD code D60 is not sufficient; the clinical definition must be satisfied.

2. Identify which factor(s) might apply. If relying on a specified drug, confirm that the drug is listed in Schedule 2 and that the treatment occurred within one year before clinical onset (or six months before onset for factor 2? Note factor 2 says "within the one year before", factor 3 says "within six months of drug therapy"). Gather pharmacy records, medical notes, and dates.

3. For benzene exposure, collect evidence of the exact concentration, duration, and dates of exposure. Workplace records, incident reports, or service documentation that shows the 8‑hour TWA exceeded 5 ppm, or that cutaneous/ingestion contact with liquids containing >1% benzene occurred on at least 30 days in the year before onset. Mere suspicion or general belief of exposure will not suffice.

4. For autoimmune disease or haematological malignancy factors, obtain a diagnosis of one of the conditions on the specified lists and confirm the timeframe (e.g. within two years before onset for autoimmune disease; within six months for haematological malignancy). Note that the autoimmune disease list includes graft versus host disease and ABO mismatched haematopoietic stem cell transplant, which are iatrogenic conditions that may themselves be service‑related.

5. For factor 3 (idiosyncratic drug reaction), evidence must show both temporal link (onset within six months of starting drug) and improvement within six months of discontinuing or tapering. This may require serial blood counts and clinical notes.

6. For clinical worsening (factors 12 and 13), ensure that the PRCA was pre‑existing before the relevant service, and that the service exposure (pregnancy or inability to obtain appropriate clinical management) materially contributed to worsening. "Inability to obtain appropriate clinical management" must be assessed against what would have been available to a comparable civilian; this is a difficult ground to prove and likely requires expert evidence.

7. Cross‑reference any underlying condition with its own SoP and comply with that SoP's factors as well. For example, if factor 10 (thymoma or thymic carcinoma) is relied upon, and thymoma has a SoP, the claimant must satisfy that SoP.

Legal practitioners should also ensure that the claim is lodged under the correct legislation (VEA or MRCA) and that the standard of proof (reasonable hypothesis for operational service; reasonable satisfaction for non‑operational service) is identified, because this SoP only creates a reasonable hypothesis. For claims under the reasonable satisfaction standard (balance of probabilities), the factors may still be relevant but the decision‑maker can also consider other evidence. However, the SoP is still binding under the VEA and MRCA for most service categories, so claimants cannot simply bypass it.